Literature DB >> 12923675

[Glutamate antagonists for treatment of neuropathic pain].

F Block1, B Habermeyer.   

Abstract

An altered glutamatergic transmission within the central nervous system is supposed to be involved in the generation and propagation of neuropathic pain. Results from experimental studies with animal models of neuropathic pain demonstrate that glutamate antagonists have a positive effect on various parameters. Clinical studies with the NMDA-receptor antagonists ketamine, amantadine, memantine and dextromethorphan and with the antiepileptics gabapentin and lamotrigine, which reduce presynaptic release of glutamate,have been performed. They have shown that most of these substances can reduce neuropathic pain. Important side effects of the NMDA receptor antagonists are hallucination and agitation, whereas tiredness and dizziness are the ones of the antiepileptics. Till now, glutamate antagonists are not drugs of first choice for the treatment of neuropathic pain. However, they are an effective alternative in case the established drugs are not helpful or are not tolerated well.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923675     DOI: 10.1007/s00482-003-0218-x

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  3 in total

1.  [Crossed central neuropathic pain syndrome after bacterial meningoencephalitis].

Authors:  K Henkel; D Bengel
Journal:  Schmerz       Date:  2005-02       Impact factor: 1.107

2.  Persistent inflammation-induced up-regulation of brain-derived neurotrophic factor (BDNF) promotes synaptic delivery of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor GluA1 subunits in descending pain modulatory circuits.

Authors:  Wenjuan Tao; Quan Chen; Wenjie Zhou; Yunping Wang; Lu Wang; Zhi Zhang
Journal:  J Biol Chem       Date:  2014-06-25       Impact factor: 5.157

Review 3.  [Antidepressants and anticonvulsive agents. Practical utility profile in pain therapy].

Authors:  V Lindner; G Deuschl
Journal:  Schmerz       Date:  2004-02       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.